About Kestrel Therapeutics
Kestrel Therapeutics is a private company based in Boston, Massachusetts, incorporated in 2020 in Delaware. It has reported $20,728,000 raised in four offerings on Form D since March 2021. Its chief executive is Frank Haluska.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jul 28, 2025 | Aug 12, 2025 | $5,000,000of $10.0M target | 6 | $833K | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Feb 7, 2025 | Feb 21, 2025 | $8,000,000of $16.0M target | 7 | $1.1M | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 28, 2021 | Jan 11, 2022 | $7,500,000of $40.0M target | 6 | $1.2M | EquityRule 506(b) | Form D ↗ |
| Mar 1, 2021 | Mar 25, 2021 | $228,000of $2.0M target | 4 | $57,000 | DebtRule 506(b) | Form D ↗ |
| Total, four offerings | $20,728,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Kestrel Therapeutics's Form D filed Aug 12, 2025.
NS
Nicholas Saccomano
Director
DP
Denis Patrick
Director
BS
Barbara Sosnowski
Director
OK
Omar Khalil
Director
AP
Andrew Phillips
Director
FH
Frank Haluska
President and Chief Executive Officer, director